Barratt J, Lafayette R, Kristensen J, Stone A, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2023;103:391-402.
PMID: 36270561